Jim Cramer Likes Johnson & Johnson Over Eli Lilly in Pharma Sector

TheStreet's Jim Cramer says Gilead (GILD) - Get Report needs to make an acquisition to jump start its business. But Cramer notes that there's a major undertone indicating the entire biotechnology group is in a bear market until the election is over. Cramer also commented on Eli Lilly (LLY) - Get Report , saying he's concerned the company's Alzheimer's drug may not be as big as he thought. He noted that his Action Alerts PLUS portfolio had to change its position on Lilly as a result. Cramer said Lilly has become a challenged company in terms of its pipeline, but within the pharmaceutical sector, Cramer said he likes Johnson & Johnson (JNJ) - Get Report . Cramer also talked about Facebook (FB) - Get Report , saying the stock is cheap when valued against 2017 and 2018 earnings estimates. Finally, Cramer discussed Buffalo Wild Wings( (BWLD) ), saying the company doesn't have aggressive momentum right now, and in fact it should a deceleration in the last quarter. Instead, Cramer likes the momentum behind McDonald's (MCD) - Get Report and Panera (PNRA) . Viewers can send Cramer questions on his Facebook page or on Twitter, use hashtag CramerQ.

At the time of publication, Jim Cramer's charitable trust Action Alerts PLUS held no positions in stocks mentioned.